Knowledge-based planning (KBP) can be used to estimate dose-volume histograms (DVHs) of organs at risk (OAR) using models. The task of model creation, however, can result in estimates with differing accuracy; particularly when outlier plans are not properly addressed. This work used RapidPlan TM to create models for the prostate and head and neck intended for large-scale distribution. Potential outlier plans were identified by means of regression analysis scatter plots, Cook's distance, coefficient of determination, and the chi-squared test. Outlier plans were identified as falling into three categories: geometric, dosimetric, and over-fitting outliers. The models were validated by comparing DVHs estimated by the model with those from a separate and independent set of clinical plans. The estimated DVHs were also used as optimization objectives during inverse planning. The analysis tools lead us to identify as many as 7 geometric, 8 dosimetric, and 20 over-fitting outliers in the raw models. Geometric and over-fitting outliers were removed while the dosimetric outliers were replaced after re-planning. Model validation was done by comparing the DVHs at 50%, 85%, and 99% of the maximum dose for each OAR (denoted as V50, V85, and V99) and agreed within À2% to 4% for the three metrics for the final prostate model. In terms of the head and neck model, the estimated DVHs agreed from À2.0% to 5.1% at V50, 0.1% to 7.1% at V85, and 0.1% to 7.6% at V99. The process used to create these models improved the accuracy for the pharyngeal constrictor DVH estimation where one plan was originally over-estimated by more than twice. In conclusion, our results demonstrate that KBP models should be carefully created since their accuracy could be negatively affected by outlier plans. Outlier plans can be addressed by removing them from the model and re-planning.
| INTRODUCTION
Knowledge-based planning (KBP) is an emerging field in radiation therapy which uses machine learning techniques to estimate radiation therapy dose. KBP can be generalized to be the automation of different steps in the creation of a plan based on past practice.
These steps can range from the estimation of field direction, 1 weights of optimization objectives, 2 and even dose distribution. 3, 4 The majority of KBP work, however, has focused on estimating dose-volume histograms (DVHs) [5] [6] [7] [8] [9] which are commonly used to evaluate plan quality and guide the inverse planning process.
Radiation treatment planning is a complex process which can result in an infinite number of plans; some of which are suboptimal. This is because the final dose distribution is dependent on the geometry of the organs at risk (OAR) with respect to the target. Other factors that can potentially affect the quality of the final plan are differences in dose prescription, 10 treatment technique, and planner experience. 11 It is because of these reasons that plan quality evaluation has been based on user experience primarily making the development of quantitative tools necessary.
KBP tools have been in development by different groups over the past few years. Wu et al. introduced the concept of the overlap volume histogram and used it to estimate the DVHs for OARs, 6 and automate the treatment planning process in head and neck (HN)
cases. 12 Zhu et al. used the distance to target histogram, support vector regression, and principal component analysis to estimate
DVHs in the context of adaptive radiation therapy. 7 Yuan et al.
proved that it is possible to quantify the complex relationship that different factors have on the final shape of the DVH. 9 This group also used their tool to exchange models that summarize plan creation strategies among different institutions, hence providing a means to standardize treatment planning. 13, 14 Moore et al. introduced a KBP tool to perform quality assurance on intensity modulated radiation therapy (IMRT) plans and reduce dosimetric variability. 15 Appenzoler et al. described a mathematical framework to estimate differential DVHs using a summation of skew-normal distributions whose parameters were fitted based on previous plans. 8 This work has being further expanded to be used in the case of intracranial lesions. 5 The work described in the previous paragraph has been done using tools developed in house. It is only more recently that a com- RapidPlan using volumetric arc therapy in hepatocellular, lung, and prostate cancer. 16, 17 Their results showed that RapidPlan models can be used to achieve clinically acceptable plans. Tol et al. evaluated the performance RapidPlan on head and neck and showed the ability to achieve clinically acceptable plans for this site. 18 These studies identified the need to investigate the proper identification of outlier plans, that is, plans that do not seem to follow the general trend of the training set and could have a negative effect on the models.
Delaney et al. systematically introduced dosimetric outliers in KBP models and found little change in the accuracy of the model. 19 This was attributed to the decreased precision of the estimated DVHs, whose lower boundary was used for planning. Their study focused on the effect of dosimetric outliers and briefly mentions the negative effect of geometric outliers on KBP models. Proper outlier analysis also helps control model over learning, meaning that the trained model only reflects the training set and not similar cases.
This manuscript describes the process used to create models to be used by a wide range of users with emphasis on the steps taken to address all types of outliers. This is the first study, to the best of our knowledge, which categorizes the different types of outliers, provides strategies to address each of them as well as examples of their effect in the model. This extended outlier analysis will benefit users who are starting to build their own KBP models. Furthermore, the models created are included in the commercial distribution of RapidPlan and we believe it is important for the user to understand the philosophy used to create the models as well as the accuracy obtained during their creation. We will show that proper outlier removal can affect the accuracy of estimated DVHs. This outlier analysis becomes particularly important when creating models that have the potential to be used by a wide range of users.
| MATERIALS AND METHODS

2.A | Overview of the algorithm
The commercial implementation of KBP uses a DVH estimation algorithm that is different from the algorithms described above. This algorithm estimates DVHs by dividing the OAR volume into four different regions: the out-of-field, in-field, leaf-transmission, and overlap region. All regions contribute to the final DVH but each region is modeled differently depending on the desired detail and accuracy.
While both the in-field and overlap regions are dependent on fluence modulation, the shapes of DVHs in the overlap region are similar across all plans. For this reason, and under the assumption that the target is the primary priority in that area, the overlap region is modeled by the mean and standard deviation of the DVHs part corresponding to that overlap area. In the in-field region, however, the shapes of the in-field DVHs vary considerably across all the plans. It is in this region where the major improvements in tissue sparing could be achieved, under the assumption that the target is the primary priority in the overlap area. Thus, this in-field region, where higher modulation is present and higher accuracy is desired, is modeled using principal component analysis (PCA) and regression techniques. PCA is used to transform the histograms into principal component scores (PCS), thus reducing the dimensionality of the problem. PCA is also used to parametrize the geometry-based expected (GED) histogram, a 3D matrix incorporating the target geometry, target dose, and treatment field geometry. Other parameters that affect the PCS of the DVH include the OAR volume, target All Prostate plans were treated using RapidArc â with two full arcs. HN treatments were treated using two partial or full arcs depending on whether the disease was unilateral or bilateral respectively.
2.B.2 | Model creation process
The This approach was followed since it was unclear how HN plans should be categorized. Even for treatments of the same site (e.g., oropharynx); there were multiple combinations of dose prescription, changes in the relative geometry of the target with respect to OARs, and number of targets. Using the largest number of plans available, and using scatter plots to identify clusters resulted in a more efficient (and practical) approach.
The models were evaluated using the coefficient of determination and the chi-squared test. In order to recognize potential outliers, the scatter plots (provided by the RapidPlan TM algorithm) were used to detect cases not fitting to the general model behavior. Scatter plots show the relationship between the dependent variable DVH PCS on independent variables and any training case appearing to be exceptionally far away from the regression line was considered as a potential outlier. In addition, potentially influential cases were determined using Cook's distance (the threshold value being roughly 3.0).
Cook's distance was used since it provides a measure of influence of an outlier by omitting the plan from the regression analysis. 20 iteratively by excluding one or two strongest influential cases (or outliers) at a time and monitoring the improvement in the trained model. The removal stopped once no more significant improvement was observed. The chi-squared test was used to monitor over-fitting.
A threshold value of 1.3 was used as an indication of no severe over-fitting.
2.B.3 | Outlier analysis
Outliers 
2.C | Models validation
The validation process consisted of using the trained models to estimate DVHs on a group patients with similar characteristics of those used to train the model. The purpose of the validation process is to provide confidence that the model does not estimate the DVH variation in the training set only. The validation set of patients were completely independent from the patients used for training. These patients had undergone treatment at our clinic, and so had clinically acceptable plans. The DVHs of the clinical plans in the validation patients were compared against the estimated DVHs obtained from the model. Estimated DVHs were subtracted from the clinical DVHs at points corresponding to 50%, 85%, and 99% of OAR maximum dose (which we will refer to a V50, V85, and V99). Yuan et al. 9 quantified this difference with respect to the prescription dose but these metrics would become irrelevant for OARs whose dose is less than 50% of the prescription dose. Instead, the doses used to compare DVHs were normalized with respect to the maximum OAR dose. Note that the V50, V85, and V99 metrics used in this study Table 2 below.
Both models were used to create plans as part of the validation process. The lower boundary of the estimated DVHs were set as optimization objectives with fixed priorities for all validation plans.
These are called line objectives and were, arbitrarily, set with a priority value of 50 for the bladder, rectum, and femoral heads. Two point objectives were set for the planning target volume (PTV) with a priority of 120: a lower V98% = 100% and an upper V102% = 0%.
The full set of optimization objectives used in the HN model is too large to be displayed in this manuscript given the large variability of HN treatments For example, different clinical metrics are requested depending on the location of the tumor and, hence, the initial optimization objectives of untrained structures. The optimization were excluded from the general prostate model and a model-specific for this category would have to be created. Once pelvic lymph nodes plans were removed, the bladder scatter plot showed that the reminder categories of prostate plans followed the same trend. Table 3 lists the values of the metrics used to evaluate the goodness of statistics for the first and final models. Figure 2 shows the scatter plot for the rectum where a wider spread can be observed Figure 6 shows the scatter plot that was initially obtained for the parotids (laterality combined as a single training structure, similarly to the femoral heads in the prostate model). Figure 7 shows the corresponding scatter plot that was obtained after two plans were replanned (dosimetric outliers) and the parotids for three plans were excluded (influential geometric outliers). Further investigations showed that these three outliers, encircled in the upper right corner, corresponded to plans with large overlaps of the parotids with the targets. In fact, similar plans in the validation set showed that these plans resulted in a third cluster (tri-polar data). These three plans were then removed since bi-polar and tri-polar data are better described by separate models. The third group of patients was excluded from the model and, instead, the model was validated including these types of plans to investigate its performance under these circumstances. Figure 7 shows the presence of two clusters corresponding to contralateral parotids (grouped in the lower left corner) and the remainder of the parotids. While the accuracy of the model can be improved by creating separate models for these two groups, this would require the user to decide which model to use. This approach is not possible if the proper model cannot be determined upfront, as was the case here, and so it was decided to merge both parotids into the same model and evaluate the accuracy resulting from this compromise. Note that this approach is different from that followed to create the prostate model, where a separate model would have to be created for high risk patients which can be easily identified.
3.A.2 | HN model
Merging the bipolar data resulted in a compromise. A direct consequence of this compromise is a larger upper estimate boundary (e.g., see the long tail of the upper estimate in Fig. 8 ). This effect is because the final DVH estimate is obtained by summing the average DVH (which is calculated from both contralateral parotids and parotids that receive larger doses) with the DVHs reconstructed from the principal components. Table 4 below summarizes the changes that were done to the first HN model along with a description of why they were made.
These changes were done in multiple iterations. Table 4 shows that a total of 20 structures were removed from the model because they were causing over-fitting. The majority of these plans resulted in over-fitting as a result of limitations in the algorithm, such as having doses on the order of the threshold dose used to define DVHs that require in-field regression vs those DVHs that do not (and that can be described by other DVH components, e.g., leaf transmission).
Over-fitting was particularly noticeable for the mandible, where the stepwise regression also returned terms corresponding to the product of PCS (belonging to different and orthogonal principal components). These products of PCS have no physical meaning and lead us to remove more plans in order to avoid them. A total of eight plans were excluded for the mandible and, even after these eight structures were removed from the model, over-fitting was still taking Figure 9 also shows the variation in DVH shape for this OAR.
As can be seen from the figure, this mostly affects cases where the mandible is receiving low doses and would require planners to attempt to reduce dose to these OAR for low doses. Table 5 shows the values of statistical parameters for the HN model. This is likely driven by the shape of the DVH for this structure which typically has to be "bent down" to meet the clinical "V40 Gy" goal ( Table 8 below). The femoral head estimates are less accurate (ranging from À2% to 3%) than those achieved for the bladder and rectum. This reduced accuracy is likely to be due to the planning technique: femoral heads are planned to remain below a maximum dose instead of well-defined dose-volume constraints which can help to shape the DVH. In addition, the DVHs for the femoral heads exhibit steep dose fall-offs, leading to large errors for small changes in dose. The values of Table 6 for the bladder and rectum can be compared to the results of Yuan et al., 9 who found estimated volumes to agree within 6% with the clinical DVHs in 71% of the cases and within 10% in 85% of the cases. The V50, V85, and V99 metrics for the bladder model of this study were within 6% in 97.5% of the cases and within 10% in 99% of the cases. The corresponding differences in the rectum were within 6% in 85% of the cases and within 0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  40  20  0   100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100  50  0  100 Note that merging of the femoral heads into a single model structure (each femoral head was contoured separately) was done
3.B | Validation results
given that the treatment technique used at our center is symmetric.
Merging the femoral heads into a single structure changed the mean values of the V50, V85, and V99 by values which were within the uncertainty (standard error of the mean). Table 7 lists the average differences between the estimated and clinical DVHs for the HN model. Parotid structures were merged into a single structure for training. The results of this table show that the largest deviations happen at the V99 metric which is closely related to the maximum OAR dose. The mean difference for the other metrics ranges from À2% to 7% and, with the exception of two cases (brainstem V85 and Pharyngeal Constrictor V85) is within À2% to 4%. The reasons for the larger discrepancy close to the maximum OAR dose may be related to the long tails of the estimated DVHs (see Fig. 8 above) . The pharyngeal constrictor is the least accurate structure; however, the steps taken to improve the model result increased accuracy for this OAR as shown in Fig. 11 . in Fig. 11 and corresponds to a mean dose of 17.6 Gy. Figure 12 compares the parotids estimated and clinical mean doses which are commonly used as a clinical tolerance. The average difference between the estimated and clinical mean doses was À0.8% AE 0.4%
with a standard deviation of 3.6%. Tables 8 and 9 list the average difference between DVHs of plans generated using the models and those from the independent clinical plans. The differences were calculated for the clinical goals most commonly used (listed in the second column). The results of Table 8 show an agreement of 0.3% for the V40 Gy metric of the rectum. This is despite the reduced accuracy of the V50 metric for the estimated DVH. This is because the line objectives are placed on the lower boundary of the estimate which coincides with the clinical DVH in many cases (see Fig. 10 ). The V50 metric on the other hand, was calculated based on the estimated average. Table 9 only shows the results for the highest dose PTV since the results for the other PTVs (intermediate and low doses) agreed within 1.2%. Table 9 also includes results for structures which were not trained due to insufficient data (structures which are contoured less frequently) and optical structures (which were also excluded from the model). The DVH metrics for the PTV agreed within 2.0% while the agreement for the OARs included in the model range from À1.6% to 2.5%. The table also shows reduced agreement for untrained OARs.
| DISCUSSION
This paper summarized the process used to build models with emphasis on the approach used to address outliers. suggested that dosimetric outliers have minimal effect on the accuracy of KBP models, instead they affected their precision. 19 Given that the models described are available to a potentially large number of users, the creation of robust models was desirable by removing influential outliers while keeping plans that provide additional information. This included the desire to create models which are both accurate and precise, hence the need to re-plan dosimetric outliers.
The models presented in this manuscript were created following a process which required multiple iterations that have to be done manually by the user and is, hence, time consuming. This made it impractical to evaluate the effect that an individual outlier would have on the models. Our results, however, show that the steps taken to create the models improved the accuracy of DVH estimates and previous tools. 9 The models in this study were compared by calculating the difference between the volume of the DVH curve in the clinical plan and the volume of the estimated DVH. These volumes were compared at three points along the x axis which corresponded to the 50%, 85% and, 99% of the maximum dose (of the clinical plan). These points were used in a previous publication 9 and provided a benchmark for model comparison. The selected metrics can also be generalized to plans with different prescriptions, where many clinical goals would be irrelevant. Another advantage of the metrics used in this study can be seen in the planning results for the femoral heads (Table 8 ). 18 There is, however, no evidence that one metric is better than the other and this topic needs further investigation. The modified V50, V85, and V99 metrics used in this study can be used to evaluate the accuracy of estimated DVHs for all plans irrespective of dose prescription and provide a reasonable way to quantify the shape of the estimated DVH.
The models were also used as optimization objectives as part of the validation process. It should be noted that while some authors have benchmarked their models by using them to guide the optimization process, 18 others have focused entirely on the accuracy of the estimated DVHs, 9,21 and others in both. 8 While the need to re-plan all plans remains debatable, we decided to use our models as optimization objectives for the validation process. This provided an end-to-end test for the models and ensures that the model does not compromise on untrained structures. The models were therefore evaluated in three different ways: (a) by analyzing the accuracy of the estimated DVHs on the training set (summarized in the goodness of fit statistics), (b) by analyzing the accuracy of estimated DVHs on an independent validation set, and (c) by using the estimated DVH to guide the inverse planning process. This therefore resulted in a rigorous model commissioning approach that gives confidence of its performance.
Planning can be done in a variety of ways, potentially leading to different results. Therefore, the planning of this study was done by means of an automated run without user interaction. This approach leads to user independent results and is more practical (due to the large number of validation patients). However, the approach is limited since the presence of untrained OARs could not be accounted for. Our results show that the models can be used by users outside of the institution where they were originally created yet preserve the planning trend. Additional planning could be conducted for cases where differences between the estimated and the original DVHs are significant since it implies potential for dose reduction (cases where the DVH was under-estimated) or increased dose (cases the DVH was over-estimated). The question of what difference is considered significant to require additional planning is still unknown and is beyond the scope of this publication.
The presence of bipolar data was evident in the bladder of the prostate model and in the parotids of the HN model. The simplest way to address bipolar data is to simply separate them as was done in the prostate model. The bipolar data for the parotids is due to ipsi-and contra-lateral parotids and its separation is more challenging as this would require a user to come up with a strategy to accurately identify these groups of parotids. Incorporation of techniques that aid in cluster classification could improve the accuracy of parotid DVH estimates. 22 
| CONCLUSION S
The creation of KBP models requires diligence since the presence of outliers can affect the accuracy of the estimated DVHs. A combination of multiple tools should be used to identify and address outliers.
The process followed to create models presented in this publication 
